Tags

Type your tag names separated by a space and hit enter

Bedaquiline: a novel antitubercular agent for the treatment of multidrug-resistant tuberculosis.
Pharmacotherapy 2014; 34(11):1187-97P

Abstract

Bedaquiline is a diarylquinoline antitubercular drug with a novel mechanism of action against Mycobacterium tuberculosis. Bedaquiline works by inhibiting bacterial adenosine triphosphate (ATP) synthase and represents the first novel class of antituberculosis agents in more than 40 years. Bedaquiline is indicated for the treatment of multidrug-resistant tuberculosis (MDR TB) in combination with at least three other antitubercular drugs when no other effective regimen is available. The recommended bedaquiline dosage is 400 mg orally once/day for 2 weeks followed by 200 mg orally 3 times/week for 22 weeks. Bedaquiline should be administered with food, which increases the bioavailability 2-fold. Bedaquiline is metabolized by cytochrome P450 isoenzyme 3A4 and is impacted by both inducers and inhibitors of this isoenzyme. Concentration-dependent bactericidal activity was observed in laboratory and murine studies. Accelerated approval was granted in the United States and European Union based on the results of two phase IIb clinical studies that used sputum culture clearance as a surrogate end point for clinical efficacy. These studies showed greater sputum culture clearance up to week 24 for the bedaquiline group compared with placebo. Common adverse events in clinical trials included nausea, arthralgia, and headache. Serious adverse events included elevated serum transaminase levels and rate-corrected QT-interval prolongation. Unexplained higher mortality was seen in patients receiving bedaquiline versus those receiving placebo. Bedaquiline is a novel agent with a unique mechanism of action and has the potential to meet a great need in patients with MDR TB who have no other treatment options. Due to safety concerns and limited clinical information, phase III trials are needed to fully determine its place in therapy.

Authors+Show Affiliations

Department of Pharmacy, Lee Memorial Health System, Fort Myers, Florida.No affiliation info available

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

25203970

Citation

Worley, Marylee V., and Sandy J. Estrada. "Bedaquiline: a Novel Antitubercular Agent for the Treatment of Multidrug-resistant Tuberculosis." Pharmacotherapy, vol. 34, no. 11, 2014, pp. 1187-97.
Worley MV, Estrada SJ. Bedaquiline: a novel antitubercular agent for the treatment of multidrug-resistant tuberculosis. Pharmacotherapy. 2014;34(11):1187-97.
Worley, M. V., & Estrada, S. J. (2014). Bedaquiline: a novel antitubercular agent for the treatment of multidrug-resistant tuberculosis. Pharmacotherapy, 34(11), pp. 1187-97. doi:10.1002/phar.1482.
Worley MV, Estrada SJ. Bedaquiline: a Novel Antitubercular Agent for the Treatment of Multidrug-resistant Tuberculosis. Pharmacotherapy. 2014;34(11):1187-97. PubMed PMID: 25203970.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Bedaquiline: a novel antitubercular agent for the treatment of multidrug-resistant tuberculosis. AU - Worley,Marylee V, AU - Estrada,Sandy J, Y1 - 2014/09/09/ PY - 2014/9/10/entrez PY - 2014/9/10/pubmed PY - 2015/7/2/medline KW - ATP synthase KW - MDR TB KW - R207910 KW - TMC207 KW - bedaquiline KW - diarylquinoline KW - multidrug-resistant tuberculosis KW - tuberculosis SP - 1187 EP - 97 JF - Pharmacotherapy JO - Pharmacotherapy VL - 34 IS - 11 N2 - Bedaquiline is a diarylquinoline antitubercular drug with a novel mechanism of action against Mycobacterium tuberculosis. Bedaquiline works by inhibiting bacterial adenosine triphosphate (ATP) synthase and represents the first novel class of antituberculosis agents in more than 40 years. Bedaquiline is indicated for the treatment of multidrug-resistant tuberculosis (MDR TB) in combination with at least three other antitubercular drugs when no other effective regimen is available. The recommended bedaquiline dosage is 400 mg orally once/day for 2 weeks followed by 200 mg orally 3 times/week for 22 weeks. Bedaquiline should be administered with food, which increases the bioavailability 2-fold. Bedaquiline is metabolized by cytochrome P450 isoenzyme 3A4 and is impacted by both inducers and inhibitors of this isoenzyme. Concentration-dependent bactericidal activity was observed in laboratory and murine studies. Accelerated approval was granted in the United States and European Union based on the results of two phase IIb clinical studies that used sputum culture clearance as a surrogate end point for clinical efficacy. These studies showed greater sputum culture clearance up to week 24 for the bedaquiline group compared with placebo. Common adverse events in clinical trials included nausea, arthralgia, and headache. Serious adverse events included elevated serum transaminase levels and rate-corrected QT-interval prolongation. Unexplained higher mortality was seen in patients receiving bedaquiline versus those receiving placebo. Bedaquiline is a novel agent with a unique mechanism of action and has the potential to meet a great need in patients with MDR TB who have no other treatment options. Due to safety concerns and limited clinical information, phase III trials are needed to fully determine its place in therapy. SN - 1875-9114 UR - https://www.unboundmedicine.com/medline/citation/25203970/Bedaquiline:_a_novel_antitubercular_agent_for_the_treatment_of_multidrug_resistant_tuberculosis_ L2 - https://doi.org/10.1002/phar.1482 DB - PRIME DP - Unbound Medicine ER -